Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion |
| |
Authors: | Baron Frédéric Frère Pascale Fillet Georges Beguin Yves |
| |
Institution: | Department of Medicine, Division of Haematology, University of Liège, Liège, Belgium. |
| |
Abstract: | We evaluated the ability of recombinant human erythropoietin (rHuEpo) therapy, given before high-dose therapy (HDT), to allow autologous peripheral blood stem cell transplantation (PBSCT) without red blood cell (RBC) transfusions. Eleven multiple myeloma patients underwent tandem HDT and autologous PBSC, receiving 500 U/kg/week rHuEpo from d 30 after initial transplant. Haemoglobin levels were 9.5 +/- 1.1 g/dl and 12.5 +/- 0.9 g/dl at the first and second transplant respectively (P < 0.001). RBC transfusions were required for 10/11 patients for the first transplant versus 1/11 for the second (P < 0.001). To conclude, a short course of rHuEpo therapy before HDT facilitates the performance of an autologous transplant without RBC transfusions. |
| |
Keywords: | autologous stem cell transplantation tandem transplantation myeloma erythropoietin recombinant erythropoietin |
本文献已被 PubMed 等数据库收录! |
|